INTRODUCTION
Knowledge of the molecular mechanisms which govern expression of the human immunodeficiency virus type 1 (HIV-1) genome is essential to understand the persistent viral replication and viral latency underlying HIV-1-associated pathogenesis. HIV-1 transcription is directed by the long terminal repeat (LTR) through interactions with a number of viral and host cell proteins, such as the transcription factors Sp1 and NF-κB (reviewed in 1,2). Viral production can be induced in response to a variety of agents which mediate their action through different transcription factors. Interleukin 6 affects viral expression through the transcription factor NF-IL6 (3) . A number of stimuli, such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) (4), reactive oxygen intermediates (5) , phosphatidylcholine hydrolysis (6), transforming growth factor-β (TGF-β) (7) and amino acid analogs (8) stimulate HIV-1 transcription by activation of the NF-κB transcription factor family (9) (10) (11) . Upon stimulation-induced nuclear translocation, NF-κB proteins activate HIV-1 gene transcription through binding to the κB enhancer motif located in the -109/-79 LTR region.
We have reported recently that the neuromodulator dopamine is involved in the regulation of HIV-1 gene expression in neuronal cells, via the transcription factor COUP-TF, acting on the proximal -68/+80 LTR region (12) . The dopamine system is involved in the control of motor, cognitive and neuroendocrine processes in the central nervous system. Dopamine mediates its effects by activating second messengers through its interaction with G-protein-coupled dopamine receptors. The action of dopamine on target cells affects multiple intracellular pathways, such as formation of cyclic AMP, inositolphosphates and arachidonic acid, and modulates cellular electrical activity by altering the properties of ion channels (13) (14) (15) . Pathways to the nucleus may involve adenyl cyclase and protein kinase A (PKA) or Ca 2+ , protein kinase C (PKC) or tyrosine kinase proteins, which regulate the activity of a number of transcription factors, such as CREB, AP-1 and COUP-TF through transcriptional and post-transcriptional events. In addition to cell surface receptor binding, dopamine is also transported in cells via specific uptake mechanisms (reviewed in 16) .
Recent studies have established that lymphocytes are also able to actively produce and transport catecholamines, such as dopamine (17, 18) . Dopamine is able to modulate peripheral blood lymphocyte activity via dopamine D3 and D5 receptors (19, 20) . However, effects of dopamine on HIV-1 expression in cells of the immune system have not been examined.
In this study, we have investigated the regulation of HIV-1 expression by the neuromodulator dopamine in T lymphocytes and in human primary peripheral blood mononuclear cells (PBMC). Our findings reveal that dopamine is able to stimulate viral replication in Jurkat T cells and in PBMC. This correlates with increased transcription from the HIV-1 LTR through the NF-κB element. Moreover, we have examined the effect of dopamine in the presence of phorbol esters and TNF-α. Finally, our results indicate that the mechanism of dopaminemediated stimulation is distinct from the classic NF-κB activation mechanism involving signal-induced NF-κB nuclear translocation, and presents similarities with the recently reported TGF-β-mediated HIV-1 activation (7).
MATERIALS AND METHODS

Materials
Cell culture media and all reagents, unless specified, were obtained from Sigma. [ 14 C]chloramphenicol was obtained from NEN Life Science.
Plasmid constructs
The LTR(LAI)-CAT and LTR(HXB2)-Luc vectors were described previously (12, 21) . LTR(HXB2)∆GC-CAT, LTR(HX-B2)∆κB-CAT, LTR(HXB2)∆κB/GC-CAT were described previously (22) . The -283/+80LTR∆κB/GC-CAT vector was constructed by isolating the EarI-HindIII LTR insert from LTR(HXB2)∆κB/GC-CAT and subcloning the blunt-ended fragment into the SmaI site of pUC19-CAT0. The GC-WAP-CAT, GCmut-WAP-CAT, κB-WAP-CAT, κBmut-WAP-CAT vectors contain respectively the wild-type and mutant (-79/-45) GC-rich or (-104/-79) NF-κB region from HIV-1 LTR (23).
Cell culture, isolation and propagation of PBMC
Jurkat T cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, 10 mM HEPES and penicillin/streptomycin (100 U/ml). Human PBMC were separated from whole blood collected from HIV seronegative donors by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation, washed thoroughly to remove contaminating platelets and cryopreserved. Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin/ml and 100 µg of streptomycin/ml. Cells were activated with 2 µg/ml phytohemaglutinin and 20 U/ml interleukin-2 for 2-3 days before HIV infection.
Transfections, CAT and luciferase assays
Cells (5 × 10 6 ) were transfected by the DEAE-dextran method with 1 pmol of reporter plasmid and 0.5 pmol of expression vector. When indicated, cells were treated 1 day after transfection with dopamine (100 µM), phorbol myristate acetate (PMA, 10 ng/ml), TNF-α (10 ng/ml; Genzyme), MG132 (10 µM) or cyclosporine A (0.5-5 µg/ml; Sandoz) and incubated for another 24 h before harvesting. Each transfection was repeated at least four times with different plasmid preparations. Chloramphenicol acetyltransferase (CAT) assays were performed as described previously (12) . Reaction mixtures containing 25 µg of proteins were incubated at 37°C for 2 h. Luciferase assays were performed with the luciferase kit obtained from Promega.
Infection and p24 ELISA assay
Jurkat cells (10 7 ) or PBMC (5 × 10 6 ) were transfected by the DEAE-dextran method with 5 µg of the proviral genome pNL4-3. After 2 h, dopamine (100 µM), PMA (10 ng/ml) or TNF-α (10 ng/ml; Genzyme) was added. Cell culture supernatants were harvested every 24 h, free virus was removed by centrifugation. Virus replication in culture was measured by the production of p24 protein by p24 viral capsid antigen ELISA (Dupont).
Electrophoretic mobility shift assays (EMSA)
EMSAs were performed with 10 µg of nuclear protein extracts in a buffer containing 1 ng of 32 P 5'-end-labeled κB probe, 1 µg of poly(dI-dC), 50 ng of sonicated salmon sperm DNA, 10 mM MgCl 2 , 25 mM KCl, 1 mM dithiothreitol, 12.5 mM HEPES, pH 7.8, 10% glycerol, 0.05% Nonidet P-40. Mixtures were incubated for 15 min at 4°C and protein-bound DNA complexes were analyzed by electrophoresis on a 6% polyacrylamide gel in 0.25× TBE (1× TBE = 89 mM Tris, 89 mM boric acid, 2 mM EDTA). For competition assays, unlabeled κB oligonucleotide was added at a 50-fold molar excess at the same time as the probe. For supershift assays, antibodies directed against NF-κBp50 (sc-1190) specific for p50 and p105, or c-Rel (sc-272) reactive with both c-Rel p75 and NF-κBp65, or NF-AT (sc-1149) reactive with NF-AT C1, C2, C3 and C4, or Ets1/Ets2 (sc-112) reactive with both Ets1 and Ets2 (Santa Cruz Biotechnology), or normal rabbit serum were mixed with nuclear proteins for 1 h at 4°C prior addition of the probe. The sequence of the κB synthetic oligonucleotides corresponds to the -108/-77 sequence of the HIV-1(LAI) LTR.
Western blot analysis
Jurkat cells (10 7 ) were harvested and washed in phosphatebuffered saline (PBS). Following a 10 min incubation at 4°C in buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 10 mM KCl, 0.5 mM EDTA, complemented with protease inhibitors), nuclei were pelleted by centrifugation. Cytoplasmic extracts were collected and stored at -80°C. Nuclear pellets were washed with PBS and incubated for 20 min at 4°C in buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, 0.5 mM dithiotreitol, complemented with protease inhibitors). Nuclear protein extracts were collected by a 2 min centrifugation at 10 000 r.p.m. and stored at -80°C. For western analysis, proteins (10 µg) were subjected to SDS-PAGE and transferred to nitrocellulose paper. Membranes were preincubated with 3% bovine serum albumin in PBS overnight at 4°C and were probed with polyclonal antibodies described above in EMSA (1:5000 dilution) for 90 min at room temperature in PBS-0.1% Tween 20 (PBST). After six washes with PBST for 5 min, membranes were incubated with peroxidase-labeled anti-rabbit antibody (1:7500 dilution) for 40 min and washed six times for 5 min in PBST. The signal was visualized by the chemiluminescence protocol (ECL, Amersham).
RESULTS
Dopamine stimulates HIV-1 transcription and replication in Jurkat T cells and in PBMC
To investigate the effect of dopamine on HIV-1 gene transcription, the LTR-CAT reporter vector containing the full-length LTR of the HIV-1 LAI strain was transfected into Jurkat cells which were either left untreated or treated for 24 h with increasing concentrations of dopamine. Analysis of CAT activity 48 h after transfection demonstrates that dopamine is able to stimulate HIV-1 gene transcription in Jurkat cells, in a dose-dependent manner, up to 3-and 4-fold with 100 and 300 µM dopamine, respectively ( Fig. 1) .
To study the effect of dopamine on viral replication in the Jurkat T cell line and in PBMC, cells were transfected with the proviral clone pNL4-3. One day post-transfection, cells were treated with 100 µM dopamine or left untreated. HIV-1 replication in the culture supernatant was monitored every 24 h over a 4-day period (Fig. 2) . Results show that in Jurkat cells, dopamine treatment led to a 3-fold enhancement of p24 antigen levels, at each time point, which correlates with the 3-fold increased levels of HIV-1 transactivation. Interestingly, a 3-fold enhancement of p24 levels was also detected in PBMC, at time points posterior to 48 h (Fig. 2) .
The NF-κ κ κ κB element is involved in dopamine-induced gene transcription from the HIV-1 LTR
We have previously shown that in neuronal cells HIV-1 gene transcription is stimulated in the presence of the transcription factor COUP-TF and dopamine through the -68/+29 proximal region of the LTR (12) . To delineate the LTR sequences responsible for dopamine-induced activation in T cells, we transfected LTR-CAT vectors containing 5' deletions of the LTR region and tested for their induction following dopamine treatment (Fig. 3) . The dopamine-induced activation was not affected by deletion of sequences upstream of position -283 (construct 2); deletion of the NF-κB binding sites up to position -89 (construct 3) dramatically reduced the uninduced expression and reduced dopamine-induced transcription by half: from 3.1 to 1.5. Further removal of the 3' half of the last NF-κB site and one Sp1 site up to position -68 (construct 4) or all three Sp1 sites up to position -40 (construct 5) completely abolished dopamineinduced transcription. These results indicate that sequences responsible for dopamine induction of LTR-driven transcription are contained within nucleotides -283 to -68.
To precisely identify the proximal promoter elements involved in dopamine responsiveness, we used LTR-CAT reporter vectors containing internal deletions. Deletion of the NF-κB and Sp1 sites within the -283/+80 LTR-CAT (construct 6) resulted in a complete lack of dopamine induction, confirming the importance of these sites in dopamine responsiveness. Deletion of the two NF-κB binding sites (construct 7) 
NF-κ κ κ κB sites are sufficient for dopamine-induced gene transcription
To precisely examine the individual role of NF-κB and Sp1 sites in dopamine responsiveness, we used constructs containing each of these sites in a heterologous background. In GC-WAP-CAT and NF-κB-WAP-CAT, the -79/-45 Sp1 sequences or the -104/-79 sequence containing the two NF-κB sites of the HIV-1 LTR, respectively, are inserted in front of the whey acidic protein (WAP) promoter containing a CAAT box and a TATA box (23) . As shown in Figure 4 , transcription directed by the Sp1-containing WAP promoter was not significantly responsive to dopamine. In contrast, with NF-κB-WAP-CAT, dopamine treatment led to a 2.7-fold stimulation, comparable to the 3.1-fold induction observed with HIV-1 LTR. As a control, the κBmut-WAP-CAT vector, which contains mutations in both NF-κB binding sites (23) , was unable to cause any dopamine responsiveness. These results demonstrate that NF-κB sites are sufficient to mediate dopamine-induced gene transcription in Jurkat cells.
Since the NF-κB element is known to mediate phorbol ester signaling, we measured as a control the induction of transcriptional activity caused by PMA treatment for 24 h. Results show that the wild-type κB-WAP promoter was stimulated 68-fold, while, as expected, the mutant promoter was not significantly affected. Interestingly, the transcriptional activity of HIV-1 LTR was stimulated 7.2-fold in the presence of PMA, which is about double of the 3.1-fold dopamine-induced stimulation (Fig. 5) . 
An inhibitor of proteasome is able to abolish dopamineinduced HIV-1 gene transcription
Activation of NF-κB is induced by pathways which are controlled by the 26S proteasome complex. The cytoplasmic NF-κB factor, complexed to the IκB inhibitor, is translocated in the nucleus following degradation of IκB by the proteasome; in addition, active NF-κB dimers are generated following processing of p105 or p100 into p50 and p52 proteins by the proteasome pathway (24, 25) . It is known that the inhibitor of proteasome MG132 prevents nuclear translocation of NF-κB and thus inhibits NF-κB-mediated LTR-driven transcription (9, 26, 27) .
To further confirm the importance of NF-κB in dopamine responsiveness, we tested whether the action of dopamine was repressed in the presence of a proteasome inhibitor. Jurkat cells were transfected with either HIV-1 LTR-CAT or κB-WAP-CAT and subsequently treated with 10 µM of MG132 in the absence or presence of dopamine. Results indicate that treatment with MG132 alone did not significantly affect LTR-driven transcription (Fig. 5, lanes 1 and 2) and decreased κB-WAP-driven transcription by half (lanes 7 and 8). As a positive control, the PMA-induced LTR-driven stimulation could be totally abolished in the presence of 10 µM of MG132 (lanes 3 and 4) . Interestingly, in the presence of dopamine, MG132 treatment totally suppressed dopamine-induced transcriptional activation of both LTR-CAT (lanes 5 and 6) and κB-WAP-CAT (lanes 9 and 10). We controlled by EMSA using nuclear extracts of cells treated by PMA or dopamine that the formation of the NF-κB complexes was abolished in the presence of MG132 (results not shown). These results clearly show that, similar to the PMA-induced activity, dopamine-induced transcriptional activity can be blocked by a proteasome inhibitor, which strongly suggests that the action of dopamine on the HIV-LTR or on a heterologous promoter containing κB sites requires the presence of NF-κB proteins.
Effect of dopamine, PMA and TNF-α α α α on HIV-1 gene transcription and replication in Jurkat cells and in PBMC
Besides PMA, various cytokines are known to activate HIV-1 gene transcription via NF-κB (25) . TNF-α was previously shown to stimulate LTR-driven CAT activity in Jurkat cells (4) . To examine the effect on HIV-1 gene transcription of the combined action of two distinct activators of NF-κB, Jurkat cells and PBMC were transfected with LTR-CAT and LTRLuc, respectively, and subsequently treated with either dopamine, PMA, TNF-α or the combination of two signaling molecules (Fig. 6A) . In Jurkat cells, the combination of PMA and dopamine, leading each to a 3.1-and 7.2-fold activation, resulted in an 11.5-fold stimulation, which corresponds to an additive effect. The most dramatic effect was obtained with the combined action of dopamine and TNF-α. While dopamine and TNF-α alone led to a 3.1-and 4.0-fold increase, respectively, the combination of dopamine and TNF-α resulted in a 15-fold synergistic transcriptional stimulation (Fig. 6A, left  panel) . In PBMC, the combination of TNF and dopamine, either in the absence or presence of PMA, led to a 5.8-fold transcriptional increase, which corresponds to an additive effect (Fig. 6A, right panel) .
We also examined the effect of the combination of these stimuli on the proliferation of HIV-1 in PBMC. HIV-1 replication in the culture supernatant was monitored over a 5-day period, following treatment with combinations of the various stimuli, dopamine, PMA or TNFα. In Figure 6B are shown the results obtained 5 days after infection. Interestingly, the combination of dopamine and PMA (lane 4), as well as dopamine and TNFα, in the absence (lane 6) or presence of PMA (lane 8) led to an additive increase in viral replication after 5 days. Since the PBMC were preactivated with PHA, it is not surprising that PMA treatment failed to further increase HIV-1 replication, as previously described (28) .
To examine whether dopamine responsiveness was mediated through a calcium-dependent and, more specifically, a calcineurindependent pathway, Jurkat cells were transfected with LTR-CAT and treated for 24 h with dopamine in the absence or presence of increasing concentrations of cyclosporine A (0.5-8 µg/ml). Cyclosporine A was unable to affect the dopamine-induced transcriptional stimulation, indicating that in Jurkat cells, dopamine does not enhance the activity of calcineurin (results not shown).
Dopamine does not change NF-κ κ κ
κB DNA binding activities and NF-κ κ κ κB levels
To examine whether dopamine treatment was able to induce κB binding activity, we performed EMSA experiments with nuclear extracts from Jurkat cells treated for various lengths of time with either dopamine or PMA as a control (Fig. 7A) . It was reported that with Jurkat nuclear extracts, EMSA analysis displays a complex pattern of binding activity, which can be affected by the salt concentration in the binding reaction and the conditions of cell culture (29) . Our results show that PMA treatment caused a large increase of two DNA-protein complexes known to be formed by NF-κB proteins (lanes 1-5). As reported previously, NF-κB activity comprises a family of DNA-binding proteins which, in PMA-stimulated Jurkat cells, give rise to two discrete DNA-protein complexes (30) . In contrast with PMA, dopamine treatment did not significantly affect the minor complex C (lanes 6-10), of electrophoretic mobility similar to the faster migrating NF-κB complex. The formation of complex C was specific, since it was competed by a 50-fold excess of the unlabeled κB oligonucleotide (Fig. 7B,  lanes 1 and 2) . The κB sequence is the binding site of distinct transcription factors, including members of the NF-κB/Rel family and the zinc finger proteins MBP1/PRII-BP1/HIV-EP1 and MBP-2 (31). To examine whether complex C was formed by proteins of the NF-κB family, we performed supershift experiments with nuclear proteins from cells treated with dopamine for 4 h, in the presence of polyclonal antibodies directed against either NF-κBp50, or p65 and c-Rel, or both proteins (Fig. 7B) . The presence of the p50 subunit in complex C was demonstrated, since addition of anti-p50 antibodies (lanes 4 and 6), but not a non-immune serum (lane 3) or anti-p65 antibodies (lane 5) abolished complex C formation and led to the up-shifting of the κB-binding activity (lanes 4 and 6). Since interactions between Ets and NF-κB/NF-AT proteins have been reported to regulate the HIV-1 enhancer activity in human T cells (32, 33) , we performed supershift experiments with antibodies directed against NF-AT (C1-C4) and Ets1/Ets2. Both antibodies were unable to affect complex C formation (results not shown), confirming that complex C contains only NF-κBp50, and no Ets or NF-AT proteins.
Since TNF-α, known to act through NF-κB, led alone and in combination with dopamine to a 4.0-and 15-fold transcriptional stimulation, respectively, we examined the EMSA pattern obtained with extracts of cells treated with either dopamine, TNFα or the combination of both signals (Fig. 7C) . As expected, stimulation with TNF-α led to the formation of a major NF-κB complex (lane 3). Surprisingly, the formation of this complex was not further increased upon stimulation with dopamine and TNFα (lane 4). This result confirms that dopamine does not induce NF-κB DNA binding activities in Jurkat cells.
To further confirm the absence of NF-κB translocation induced by dopamine, we measured the levels of p50, p65 and After 24 h, they were treated with dopamine (100 µM), PMA (10 ng/ml), TNF-α (10 ng/ml), alone or in combination as indicated. The production of p24 antigen in the supernatant was evaluated every 24 h for 5 days in two independent experiments. Only the time point after 5 days is shown.
IκB-α proteins in nuclear and cytoplasmic extracts of Jurkat cells treated with dopamine over a 2 h period (Fig. 8) . Western blot analysis revealed that p50, p65 and IκB-α proteins were located mostly in the cytoplasmic fraction, with a low amount in the nuclear fraction. Interestingly, protein levels were unchanged in each fraction upon dopamine treatment, over a 2 h period. This result is consistent with and confirms the previous observations, showing unchanged DNA binding activity of NF-κB (Fig. 7) .
DISCUSSION
Here our studies reveal that the neuromodulator dopamine can contribute, by itself or in the presence of cytokines or other NF-κB activating agents, to increase HIV-1 gene expression in cells of the immune system. In the endocrine system, dopamine is synthesized by chromaffin cells present in the adrenal glands, and is secreted into blood vessels following various stimuli, especially stress conditions (34) . Recently, cells of the immune system, T lymphocytes, were also discovered to synthesize, transport and bind catecholamines, such as dopamine (17) (18) (19) (20) . It was therefore intriguing to test whether this neuromodulator, whose endocrine-mediated secretion in the immune sytem is stress dependent, affects HIV-1 gene expression.
Our experiments reveal that dopamine is able to stimulate viral replication in the Jurkat T cell line as well as in PBMC, which correlates with increased transactivation from the HIV-1 LTR. Moreover, we show that dopamine, in the presence of the cytokine TNF-α, leads to a synergistic 15-fold transcriptional stimulation of the HIV-1 genome in T cells and to an additive effect in PBMC. TNF-α is known as a potent inducer of HIV-1 transcription and replication (4, 35) . Elevated levels of various cytokines, including TNF-α, IL-1, IL-6 and TGF-β, are detected in the sera of late stage disease of HIV-1-infected patients. These cytokines stimulate viral replication and contribute to HIV-1 pathogenesis (reviewed in 26). Our data reveal that the combination of dopamine and TNF-α is a potent mediator of increased HIV-1 gene expression.
We further demonstrate that dopamine responsiveness is mediated through the NF-κB sites of the HIV-1 LTR. A minimal κB-WAP promoter containing two κB sites, but not a mutated κBmut-WAP region, was also sufficient for dopaminemediated stimulation. Thus, dopamine represents a new member on the list of stimuli which are κB-mediated transcriptional activators (25) .
The NF-κB/Rel family contains five DNA-binding members, p50, p52, p65/RelA, c-Rel and RelB (11) . Our supershift results indicate that p50 proteins are present in nuclear extracts at a low constitutive level, and bind to the κB DNA site. Surprisingly, in contrast with PMA and TNF-α, dopamine treatment did not change NF-κB binding activity. These data establish that dopamine-induced LTR-driven transcription through the NF-κB sites does not require modification of the NF-κB DNA binding activity. These observations correlate with our western blot results, which show that in our culture conditions, Jurkat cells contain a small nuclear fraction of p50 and p65 NF-κB proteins, which are unaffected by dopamine treatment. It is well established that NF-κB is retained in the cytoplasm, through its association with the IκB family of proteins. Cytosolic IκB-α has a half-life of 1-2 h, and is rapidly degraded upon stimulation by activating agents such as phorbol esters, IL-1 and TNF-α (26, 36) . We show that IκB-α levels are unaffected by dopamine stimulation, confirming that dopamine does not induce NF-κB nuclear translocation. Taken together our findings reveal a mechanism for HIV-1 gene activation by NF-κB, through unchanged DNA binding activities. Similar results were recently reported in the activation of HIV-1 gene expression upon TGF-β treatment; HaCaT cells contain a constitutive fraction of NF-κB proteins in the nuclei, unaffected by TGF-β stimulation (7) .
The importance of the proteasome pathway for NF-κB activation has been well established. NF-κB molecules sequestered in the cytoplasm by the inhibitor IκB are translocated within the nuclei following degradation by the proteasome. In addition, formation of p50 is generated by processing of the N-terminal portion of p105 by a proteasome-mediated process (11, 24, 37) . We show here that a proteasome inhibitor which completely clears the nuclei from all NF-κB molecules, totally abolished dopamine-induced stimulation. This repression of dopamine responsiveness by a proteasome inhibitor suggests that the fraction of NF-κB proteins present in the nuclei is both sufficient and essential to mediate dopamine action. It therefore appears that dopamine, to play its role as a transcriptional activator, requires the action of another stimulus which first induces nuclear translocation of NF-κB. Indeed, in HIV-1 infected T cells, autocrine secretion of TNF-α was shown to control HIV-1 replication because of its ability to maintain elevated NF-κB in the nucleus (38) .
A constitutive NF-κB activity was also described in neurons (39). Our previous results have shown that in neuronal SK-N-MC cells, dopamine treatment alone is unable to affect HIV-1 transcription. In these cells, dopamine stimulates transcription in the presence of increased levels of the nuclear receptor COUP-TF via the proximal -68/+80 LTR region (12) . Similarly, our preliminary data indicate that in Jurkat cells, dopamine responsiveness can be mediated by overexpressed COUP-TF and/or CREB proteins via the proximal -68/+80 LTR region. These data reveal a variety of molecular mechanisms by which dopamine modulates HIV-1 gene transcription. Here our data in cells of the immune system stress the fact that dopamine alone is able to activate HIV-1 gene transcription through NF-κB.
The classic NF-κB activation mechanism, triggered by a number of extracellular inducers such as phorbol esters, TNF-α and oxygen peroxide, involves activation of a protein kinase that phosphorylates IκB and p105, followed by degradation of IκB, and nuclear translocation of NF-κB (40, 41) . Recent studies have demonstrated the existence of a second signaling pathway, distinct from the IκBα degradation and NF-κB nuclear translocation mechanism. Overexpression of p21(CIP1/WAF1) in Jurkat cells stimulated HIV-1 gene transcription without inducing changes in NF-κB DNA binding activity (42) . TGF-β was found to activate NF-κB proteins present constitutively in the nuclei of HaCaT cells, through a yet unidentified pathway (7) . Similarly, a second signaling pathway triggered by IL-1 and TNF-α which confers NF-κB transcriptional competency was identified in A549 epithelial cells (43) . Here our data also reveal the existence of a dopamine-induced pathway distinct from the classic NF-κB activation mechanism. Recently, the transcriptional activity of NF-κB was found to be stimulated through phosphorylation of p65 by PKA (44) . Moreover, phosphorylation of p50 was demonstrated to be a key step in the regulation of NF-κB in adenovirus transformed cells (45) . Such a scenario involving increased phosphorylation of p50 induced by dopamine signaling may explain NF-κB activation by dopamine, as well as the synergistic effect with TNF-α. Our data further reveal that the dopamine-mediated effect does not require signaling through the calcium-activated phosphatase calcineurin, which activates nuclear import of NF-AT transcription factors (46, 47) . Clearly, further studies are needed to elucidate the precise molecular mechanisms underlying NF-κB activation by dopamine, as well as the dopamine signaling pathway in T cells. It will also be interesting to examine whether the action of dopamine is mediated by cellular uptake or by binding to the cell surface dopamine receptors.
